antidepressants

This article was originally published on Psychedelic Spotlight and appears here with permission.  New study reveals distinct effects of escitalopram (Lexapro) and psilocybin on brain responses to emotions, highlighting the unique approaches of these treatments in addressing depression....

According to a scientific study published Wednesday in Nature, a group of computational biologists might have found therapeutic potential in a handful of LSD-adjacent molecules. They generated 3D iterations of more than 75 million related molecules that don’t actually exist but could,...

By WeedMaps News' Shelley Levitt, provided exclusively to Benzinga Cannabis. You don't need a study to recognize that mood elevation is one of the prime reasons people consume marijuana. It is, after all, called “getting high.”  Still, studies do exist, such as one in...

This article was originally published on The Green Fund and appears here with permission. If you're on antidepressants, you may be wondering if it's safe to smoke cannabis. The quick answer is: yes, it is safe to smoke weed while taking SSRIs. However, there are a few things you should keep...

Psychedelics-focused biotech company Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) announced the publication of its first data on the interaction of a selective serotonin uptake inhibitor, known as escitalopram, with an acute response to psilocybin in humans. The publication is based...

Seelos Therapeutics Inc (NASDAQ: SEEL) has announced data from Part 1, the open-label cohort, of its Proof-of-Concept study of SLS-002 for acute suicidal ideation and behavior in patients with Major Depressive Disorder. On depression scale, 76.5% response rate on Day 1 (n=17),...

Alkermes Plc (NASDAQ: ALKS) shares were trading down Friday as the Street weighed reports of regulatory setbacks for the biopharma.  What Happened The Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee...

SAGE Therapeutics Inc (NASDAQ: SAGE) has had a laudable 109-percent run in recent months after meeting primary endpoints in multiple trials and securing regulatory approvals.  It found further reason to celebrate Monday with the conversion of a new Street advocate. The Rating Morgan Stanley...